» Articles » PMID: 29746495

Tacrolimus Intra-patient Variability is Not Associated with Chronic Active Antibody Mediated Rejection

Overview
Journal PLoS One
Date 2018 May 11
PMID 29746495
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic active antibody mediated rejection (c-aABMR) is a major cause of long-term kidney allograft loss. It is hypothesized that frequent sub-therapeutic exposure to immunosuppressive drugs, in particular tacrolimus (Tac), is a risk factor for the development of c-aABMR. The intra-patient variability (IPV) in Tac exposure may serve as a substitute biomarker for underexposure and/or non-adherence. In this study, the association between Tac IPV and the development of c-aABMR was investigated.

Methods: We retrospectively included 59 patients diagnosed with c-aABMR and compared them to 189 control patients matched for age, year of transplantation and type of kidney donor. The Tac IPV was calculated from pre-dose tacrolimus concentrations measured over a 3 year period preceding the diagnosis of c-aABMR. The mean Tac predose concentrations (C0), Tac IPV, renal allograft function and graft survival were compared between the groups.

Results: Tac IPV was 24.4% for the cases versus 23.6% for the controls (p = 0.47). The mean Tac C0 was comparable for the cases (5.8 ng/mL) and control patients (6.1 ng/mL, p = 0.08). Only in the c-aABMR group a significant decline in both mean Tac C0 and allograft function over the timespan of 3 years was observed (p = 0.03 and p<0.001). Additionally, in the group of c-aABMR patients a high IPV was associated with inferior graft survival (p = 0.03).

Conclusions: A high Tac IPV per se does not predispose to the development of c-aABMR but is associated with inferior graft survival once c-aABMR is diagnosed.

Citing Articles

HLA class, calcineurin inhibitor levels, and the risk of graft failure in kidney recipients with donor-specific antibodies.

Beland M, Lapointe I, Cote I, Lesage J, Houde I, Wagner E Front Immunol. 2024; 15:1493878.

PMID: 39635538 PMC: 11614807. DOI: 10.3389/fimmu.2024.1493878.


Age-Related Differences in Rejection Rates, Infections, and Tacrolimus Exposure in Pediatric Kidney Transplant Recipients in the CERTAIN Registry.

Baghai Arassi M, Feisst M, Krupka K, Awan A, Benetti E, Duzova A Kidney Int Rep. 2024; 9(11):3265-3277.

PMID: 39534206 PMC: 11551099. DOI: 10.1016/j.ekir.2024.08.025.


Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation.

Morais M, Soares M, Costa G, Guerra L, Vaz N, Codes L World J Transplant. 2023; 13(5):254-263.

PMID: 37746041 PMC: 10514747. DOI: 10.5500/wjt.v13.i5.254.


The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice.

van den Broek D, Meziyerh S, Budde K, Lefaucheur C, Cozzi E, Bertrand D Transpl Int. 2023; 36:11321.

PMID: 37560072 PMC: 10408721. DOI: 10.3389/ti.2023.11321.


Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots.

Betjes M, De Weerd A Front Med (Lausanne). 2023; 10:1215167.

PMID: 37502354 PMC: 10368955. DOI: 10.3389/fmed.2023.1215167.


References
1.
Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers D . High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016; 16(10):2954-2963. DOI: 10.1111/ajt.13803. View

2.
Haas M, Sis B, Racusen L, Solez K, Glotz D, Colvin R . Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14(2):272-83. DOI: 10.1111/ajt.12590. View

3.
Borra L, Roodnat J, Kal J, Mathot R, Weimar W, van Gelder T . High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010; 25(8):2757-63. DOI: 10.1093/ndt/gfq096. View

4.
Whalen H, Glen J, Harkins V, Stevens K, Jardine A, Geddes C . High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. Transplantation. 2016; 101(2):430-436. DOI: 10.1097/TP.0000000000001129. View

5.
Gallagher H, Sarwar G, Tse T, Sladden T, Hii E, Yerkovich S . Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. J Heart Lung Transplant. 2015; 34(11):1442-8. DOI: 10.1016/j.healun.2015.05.028. View